Perhaps you think it's impossible to score another 1,000% gain off this "tech titan" stock. Think again. An unusual strategy lets you virtually "recreate" gains off the biggest companies you thought had come and gone. CLICK HERE to see how it works.
Drug Companies: A Powerhouse of Profits
by The Investment U Research Team
A couple of interesting news items came out in the past few days. One, a research report showing how expensive treatment is for childhood mental issues. It also showed that in 2006 over 13 million children were treated for asthma at a cost of $8 billion.
The other a study that finds more Americans than ever are taking some sort of prescription for mental illness – 73% more than in 1996.
What’s interesting, apart from the fact that we seem to be overmedicating as a society, is that the numbers of patients and the costs of treatments spell hundreds of billions in profits for healthcare and drug makers.
Taking a look at the eleven largest, we find that their market caps total almost $900 billion. That’s a trillion dollars in market value within a handful of companies.
Merck and Co. (NYSE: MRK), Schering-Plough (NYSE: SGP), GlaxoSmithKline ADR (NYSE: GSK), Bristol Myers Squibb (NYSE: BMY) Sanofi-Aventis ADR (NYSE: SNY), AstraZeneca ADR (NYSE: AZN), Johnson & Johnson (NYSE: JNJ), Roche Holding Ltd ADR (OTC: RHHBY) Novartis AG ADR (NYSE: NVS), Eli Lilly & Co (NYSE: LLY) and Wyeth (NYSE: WYE) represent a powerhouse of pharmaceuticals and drug development.
And while we’ve talked before about the potential for mega-mergers, looking at the size of the playing field one discovers that for the most part, these companies are relatively the same size.
The question is whether by merging, and growing larger they will be able to cut redundant overhead for these transactions to make sense. Is there a market cap size where these firms are able to run most effectively, most efficiently, and most profitably?
Companies mentioned in this article: MRK, SGP, GSK, BMY, SNY, AZN, JNJ, RHHBY, LLY and WYE
- Novartis Sees Profits In Alcon… Why You Should Too
- Two Pharmas Are Better Than One… Here Are the Ones to Buy in This Merger-Mad Industry
- Emerging Market for Pharma
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed